CD40–Tumor necrosis factor receptor-associated factor 6 protein-protein interaction (CD40-TRAF6 PPI)

CD40–TRAF6 protein-protein interaction mediates a crucial signaling axis in immune cells and stromal cells. CD40, a TNFR family receptor, upon activation, recruits TRAF6 through a specific motif in its cytoplasmic tail, enabling TRAF6 to initiate NF-κB, MAPK, and other downstream signaling pathways. This interaction governs cellular responses including inflammation, cell proliferation, and apoptosis, and is implicated in the pathogenesis of atherosclerosis, cancer, and metabolic syndromes. Targeting this interface with selective inhibitors is being explored as a strategy to treat inflammatory and cardiovascular diseases, as well as to modulate anti-tumor immunity. Blocking CD40–TRAF6 signaling can alter immune cell recruitment and phenotype, affect tissue remodeling, and modulate disease outcomes[3][4][5][1].

Other names

CD40-TRAF6 interfaceCD40-TRAF6 complexCD40-TRAF6 binding

Inhibition of CD40-TRAF6 interaction (prevents downstream proinflammatory and proatherogenic signaling) Blockade of NF-κB and MAPK pathway activation (key downstream pathways)